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T cell acute lymphoblastic leukemia (T-ALL) is 
an aggressive cancer of immature T cell pro-
genitors that often shows aberrant activation of 
NOTCH1 and PI3K–Akt pathways. Activating 
mutations of Notch1 occur in >50% of cases of 
T-ALL (Weng et al., 2004), whereas mutations 
in  related  Notch  pathway  elements  such  as 
Sel10/Fbw7 occur in 8–16% of cases (O’Neil 
et al., 2007; Thompson et al., 2007). PI3K–Akt 
pathway  activation  occurs  in  >85%  of  cases 
(Silva et al., 2008) via diverse mechanisms,   
including mutation or inactivation of PTEN 
(Kawamura et al., 1999; Perentesis et al., 2004; 
Maser et al., 2007; Palomero et al., 2007; Silva 
et al., 2008; Gutierrez et al., 2009) and muta-
tion of PIK3 and Akt (Kawamura et al., 1999; 
Gutierrez et al., 2009). Activation of PI3K–Akt 
has been shown to collaborate with Notch in 
leukemogenesis (Medyouf et al., 2010), enhance 
growth of established leukemias (Chiarini et al., 
2009; Cullion et al., 2009; Levy et al., 2009; 
Sanda et al., 2010), and in some contexts to   
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T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer of immature T cells 
that often shows aberrant activation of Notch1 and PI3K–Akt pathways. Although muta-
tions that activate PI3K–Akt signaling have previously been identified, the relative contri-
bution of growth factor-dependent activation is unclear. We show here that pharmacologic 
inhibition or genetic deletion of insulin-like growth factor 1 receptor (IGF1R) blocks the 
growth and viability of T-ALL cells, whereas moderate diminution of IGF1R signaling com-
promises leukemia-initiating cell (LIC) activity as defined by transplantability in syngeneic/
congenic secondary recipients. Furthermore, IGF1R is a Notch1 target, and Notch1 signaling is 
required to maintain IGF1R expression at high levels in T-ALL cells. These findings suggest 
effects of Notch on LIC activity may be mediated in part by enhancing the responsiveness 
of T-ALL cells to ambient growth factors, and provide strong rationale for use of IGF1R 
inhibitors to improve initial response to therapy and to achieve long-term cure of patients 
with T-ALL.
©  2011  Medyouf  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first   
six months after the publication date (see http://www.rupress.org/terms). After   
six months it is available under a Creative Commons License (Attribution–Non-
commercial–Share Alike 3.0 Unported license, as described at http://creativecom-
mons.org/licenses/by-nc-sa/3.0/).
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samples (Weng et al., 2004; Weng et al., 2006; Medyouf   
et al., 2010). For mouse cells, we examined primary leuke-
mias  derived  by  retroviral  transduction/transplantation  of 
bone marrow with an activated form of NOTCH1 termed 
E (Pear et al., 1996). To confirm IGF1R-stimulated PI3K–
Akt in these contexts, we pulsed serum-starved leukemia cells 
with recombinant IGF-1 and measured phospho-Akt activa-
tion by flow cytometry. We observed that both human and 
mouse leukemia cells respond robustly to IGF-1 stimulation 
under these conditions (Fig. S1).
Pharmacologic inhibition of IGF1R compromises  
T-ALL cell growth
To assess the extent to which T-ALL cells are dependent on 
IGF1R signaling, we used pharmacologic IGF1R inhibitors. 
Most small molecule IGF1R inhibitors also affect insulin re-
ceptor caused by their close homology and at higher doses 
may be expected to cross react with more distantly related 
receptor tyrosine kinases. One such inhibitor, BMS-536924 
(Wittman et al., 2005), substantially inhibited growth/prolif-
eration of both mouse and human leukemia cells in vitro 
(Fig. 2 and Fig. S2). Primary leukemia cells were generally 
more sensitive to BMS-536924 with IC50 values in the 0.1–
1.0 µM range, whereas established cell lines required some-
what higher doses (2–4 µM) to achieve similar effects. As 
expected, BMS-536924 completely suppressed Akt activa-
tion by both IGF-1 and insulin in human and mouse T-ALL 
cells (Fig. S1).
We next examined whether blocking antibodies against 
IGF1R, which might be expected to exhibit a higher degree 
of specificity than small molecule kinase inhibitors, would 
recapitulate  effects  seen  with  BMS-536924.  The  IGF1R-
blocking antibody IR3 substantially inhibited proliferation 
in three of four primary human leukemias tested (Fig. 2 B, 
rightmost column). Notably, the one resistant case (K419) 
expressed lower levels of IGF1R compared with the others 
relieve  dependence  on  Notch  signaling  (Palomero  et  al., 
2007). For cases that lack such mutations, however, the mech-
anisms that support activation of the pathway are unknown. 
More generally, it is also unknown to what extent growth 
factor–dependent stimulation of cognate receptor tyrosine   
kinases (RTKs) contributes to the net signaling output.
Although previous works have focused on the role of   
IL-7 signaling in T-ALL, including effects on downstream 
PI3K–Akt  activation  (Dibirdik  et  al.,  1991;  Barata  et  al., 
2004a,b,c, 2005; González-Garcia et al., 2009; Shochat et al., 
2011;  Silva  et  al.,  2011),  we  considered  that  insulin-like 
growth factor (IGF)-1 receptor (IGF1R) may also play an 
important role. IGFs and their receptors regulate normal cell 
growth and contribute to transformation and growth of ma-
lignant cells in many contexts (Pollak et al., 2004). IGF1 and 
IGF2 bind to IGF1R, a transmembrane receptor tyrosine   
kinase (RTK), thereby initiating a cascade of downstream 
phosphorylation events that bifurcates along both PI3K–Akt 
and Ras–Raf–MAPK pathways. PI3K–Akt activation leads 
to enhanced cellular metabolism and protein synthesis via 
mTOR and enhanced survival via BAD/Bcl2, p53, NF-kB, 
and FOXOs, whereas Ras–Raf–MAPK activation generally 
results in increased cellular proliferation (Pollak et al., 2004; 
Greer and Brunet, 2005). Signaling through IGF1R has also 
been implicated in self-renewal of stem cells, both in embry-
onic (Bendall et al., 2007) and hematopoietic (Ivanova et al., 
2002) contexts.
RESULTS
IGF1R is broadly expressed in T-ALL
To begin to address a potential role for IGF1R in T-ALL, we 
assessed IGF1R expression in mouse and human T-ALL cells. 
Analysis of IGF1R by Western blot and flow cytometry re-
vealed IGF1R was expressed in all cases examined, albeit at 
varying levels (Fig. 1). For human cells, we examined both 
established cell lines and xenograft-expanded primary human 
Figure 1.  IGF1R is expressed broadly in 
human and mouse T-ALL. (A and B) Western 
blot and (C and D) flow cytometric analysis of 
total and surface IGF1R protein expression, 
respectively, from human cell lines (A and C), 
primary mouse leukemias (B) derived by retro-
viral transduction/transplantation of bone 
marrow with an activated form of Notch1 
termed E, and xenograft-expanded primary 
human samples (D). Western blot controls in 
(B) are mouse embryonic fibroblasts derived 
from IGF1Rnull mouse embryos (R) and the 
same cells stably transfected with an IGF1R 
cDNA expression construct (R+). At least 
20,000 events were collected within each  
gate for all flow cytometry assays. Data de-
picted are representative of at least two inde-
pendent experiments.JEM Vol. 208, No. 9 
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IGF1R+/+ E leukemias (Fig. 3, C and D; and not depicted). 
Importantly, we confirmed that IGF1Rneo/neo E leukemias 
expressed reduced levels of full-length IGF1R protein (32 ± 
20% of levels observed in IGF1R+/+ E leukemias, n = 7; 
Fig. 3 E and not depicted).
Reduced IGF1R signaling compromises leukemia-initiating 
cell (LIC) activity
To  explore  whether  the  increased  latency  observed  for   
IGF1Rneo/neo E leukemias might be caused by delayed trans-
formation or a reduced net proliferative rate, we performed 
serial transplantation of IGF1R+/+ and IGF1Rneo/neo E leu-
kemias into syngeneic/congenic recipients by tail vein injec-
tion.  Unexpectedly,  we  observed  that  only  a  subset  of 
IGF1Rneo/neo primary leukemias was capable of transferring 
disease to secondary recipients. Among 11 independent   
primary leukemias assessed, 7 (64%) were nontransplantable, 
2 (18%) were transplantable in a minority of recipients, and   
2 (18%) were fully transplantable, including one with pro-
longed latency (Fig. 4 A). In contrast, all IGF1R+/+ primary 
leukemias were fully transplantable and exhibited short laten-
cies. We also performed tertiary and quarternary transplants 
for a subset of cases. The IGF1Rneo/neo leukemia with pro-
longed latency in secondary recipients (#3115) failed to   
produce disease in tertiary recipients, whereas the other trans-
plantable IGF1Rneo/neo leukemia (#3105) and all IGF1R+/+ 
leukemias produced short latency disease in all tertiary and 
quarternary recipients (Table S1). Notably, injection of   
IGF1Rneo/neo leukemia cells directly into the femoral bone 
marrow space of recipient mice failed 
to produce leukemia, suggesting that 
their defect in transplantability is not 
caused  by  impaired  homing  to  the 
bone marrow (Fig. 4 B). Thus, these 
results indicate that although moder-
ate levels of IGF1R signaling are suffi-
cient for expansion of bulk leukemia 
cells,  higher  levels  are  required  to   
(Fig. S3) and showed minimal response to IGF-1 stimulation 
(unpublished data), suggesting the effect of BMS-536924 on 
this particular tumor may be mediated by inhibition of insulin 
receptor. In contrast, case M69 is highly sensitive to IR3, 
but largely resistant to BMS-536924, raising the possibility of 
either off-target antibody effects or inherent drug resistance. 
Notwithstanding these exceptions, the overall results support 
that pharmacologic inhibition of IGF1R signaling can signif-
icantly inhibit the growth of most T-ALL cells.
Generation of T cell leukemias with reduced IGF1R signaling
We next used a genetic approach to further explore the   
effects of reduced and/or complete loss of IGF1R on T-ALL 
cells. Specifically, we generated primary mouse T cell leuke-
mias  by  transduction  of  bone  marrow  from  conditional 
IGF1R mice with Notch1(E) retrovirus, followed by trans-
plantation into congenic WT recipients. The conditional   
allele used, IGF1Rneo, carries loxP sites flanking the third 
exon, but also retains a loxP-flanked neo cassette within the 
second intron (Fig. 3 A). This neo cassette interferes with 
normal transcript splicing and results in reduced expression   
of full-length IGF1R protein in homozygous IGF1Rneo/neo 
cells (Holzenberger et al., 2000). Despite the decreased level 
of IGF1R expression, we were able to generate primary 
IGF1Rneo/neo leukemias with Notch1(E) retrovirus, albeit with 
slightly increased latency as compared with WT background 
(median survival 64.5 vs. 51.5 d; Fig. 3 B). All other disease 
parameters (penetrance, immunophenotype, histology, disease 
distribution, and extent) were highly comparable to control 
Figure 2.  Pharmacologic inhibition of 
IGF1R blocks growth of T-ALL cells. Flow 
cytometric analysis of cell proliferation by 
BrdU incorporation after treatment with a 
small molecule IGF1R inhibitor (BMS-
536924) versus DMSO vehicle (mock), or 
IGF1R blocking antibody (IR3), for 48–72 h 
in vitro. (A) Three representative indepen-
dent primary mouse Notch1(E) leukemias 
(#324, #327, #329). (B) Four independent 
xenograft-expanded primary human T-ALL 
samples (D115, K419, K424, and M69).  
(C) Two human T-ALL cell lines (ALLSIL and 
HPBALL). Error bars indicate standard deviation 
for assays performed in triplicate. Data de-
picted are representative of at least three 
independent experiments.1812 Notch-IGF1R signaling supports LICs in T-ALL | Medyouf et al.
compared with controls (Fig. S4, A–E). 
Furthermore, leukemia cells explanted 
from  moribund,  untreated  animals 
(8 wk post-transplant) and cultured 
with  4-hydroxytamoxifen  (4-OHT) 
in vitro to induce deletion of IGF1R 
also demonstrated growth arrest and 
loss of viability (Fig. S4 F). 4-OHT 
treatment showed no discernible toxic effects on control 
IGF1Rneo/neo Rosa26+/+ leukemia cells. Additionally, prelimi-
nary  results  from  mice  engrafted  with  a  T-ALL  cell  line 
(144CLP) derived from a mouse KrasG12D tumor (Chiang et al., 
2008) show that treatment with BMS-754807, a potent 
IGF1R inhibitor currently in clinical development (Carboni 
et al., 2009), significantly prolonged survival (Fig. S5), thus 
corroborating the genetic deletion results. Collectively, these 
data support that abrogation of IGF1R signaling impedes   
T-ALL  cell  growth/survival  and  interferes  with  disease 
establishment/progression.
Transplantable IGF1Rneo leukemias show evidence  
for downstream compensation
Our observation that a minority of IGF1Rneo/neo leukemias is 
transplantable suggests secondary alterations may be selected 
for in vivo that compensate for reduced IGF1R signaling. 
Despite the known frequency of PTEN loss and PIK3CA/
PIK3R1 mutations in T-ALL (Maser et al., 2007; Palomero 
et al., 2007; Gutierrez et al., 2009), we were unable to detect 
support LIC activity as assayed by serial transplantation in 
syngeneic/congenic recipients.
Deletion or pharmacologic inhibition of IGF1R prevents 
disease establishment/progression
To assess the effect of complete loss of IGF1R in T-ALL 
cells,  we  transduced  bone  marrow  from  IGF1Rneo/neo  
Rosa26CreERT mice with Notch1(E) retrovirus, followed by 
transplantation into WT recipient mice. At 4 wk after trans-
plant, peripheral blood was assessed by flow cytometry to 
confirm engraftment by GFP+ CD4+ CD8+ leukemia cells. 
Mice were then divided into equivalent control versus treat-
ment groups, and the latter was fed tamoxifen-containing 
chow (1 g/kg) for a 7-d period to induce deletion of IGF1R. 
Mice from both groups were then sacrificed, and tissues were 
harvested. Preliminary results show that tamoxifen-treated 
mice  demonstrate  significantly  lower  levels  of  disease  in-
volvement in all tissues examined (bone marrow, spleen, and 
thymus), and leukemia cells from tamoxifen-treated animals 
exhibited lower proliferative and higher apoptotic indices as 
Figure 3.  Primary mouse T cell leukemias 
are generated efficiently by activated 
Notch1 despite reduced IGF1R expression. 
(A) Schematic of the IGF1Rneo allele. The re-
tained neo cassette within the second intron 
results in reduced expression of full-length 
IGF1R protein in IGF1Rneo/neo mice  
(Holzenberger et al., 2000). (B) Survival of mice  
transplanted with retroviral Notch1(E)-
transduced bone marrow from either WT 
(IGF1R+/+; n = 6) or IGF1R hypomorph  
(IGF1Rneo/neo; n = 14) donor animals. ***, P < 
0.0001 (Log-rank test). (C) Spleen and liver 
organ weights at necropsy of individual mor-
bid mice transplanted with Notch1(E)- 
transduced bone marrow from IGF1R+/+ (n = 6) 
and IGF1Rneo/neo (n = 11) backgrounds. Error 
bars indicate standard deviation. (D) Immuno-
phenotypic analysis of representative primary 
mouse E leukemias derived on the IGF1Rneo/neo 
background. (E) Western blot analysis of total 
IGF1R protein expression in representative 
primary mouse E leukemias on IGF1R+/+, 
IGF1Rneo/+, and IGF1Rneo/neo backgrounds.  
R+ and R mouse embryonic fibroblast 
staining controls and Erk2 loading control are 
indicated. Data depicted in D and E are repre-
sentative of at least seven independent samples.JEM Vol. 208, No. 9 
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responsive to IGF-1, and are comparable to nontransplant-
able IGF1Rneo/neo leukemias in this regard (Fig. 5 D). We also 
noted the one IGF1Rneo/neo leukemia exhibiting very short 
latency in secondary recipients (#3105) had unusually high 
levels of pAkt at steady state (twofold greater than IGF1R+/+ 
cells; Fig. 5 E). The elevated pAkt in these cells was not re-
duced even after prolonged serum starvation (unpublished 
data), suggesting the presence of some constitutively activat-
ing mutation that confers growth factor independence. In 
contrast, we have not found similarly compelling evidence 
these alterations in any of the transplantable E-IGF1Rneo/neo 
leukemias (Fig. 5, A and B; and not depicted). We thus con-
sidered that enhanced responsiveness to growth factor stimu-
lation  could  compensate  for  reduced  IGF1R  expression.   
In fact, transplantable leukemias #3112 and #3115 demon-
strated enhanced pAkt response to serum stimulation as com-
pared with nontransplantable leukemias, though not to the 
degree exhibited by IGF1R+/+ cells (Fig. 5 C). We excluded 
the possibility that IGF1R itself was up-regulated as trans-
plantable IGF1Rneo/neo leukemias remained only minimally 
Figure 4.  Mouse T cell leukemias with reduced IGF1R expression are defective in serial transplantation. Survival of mice transplanted with 
primary mouse E leukemia cells from either IGF1R+/+ or IGF1Rneo/neo backgrounds by i.v. (A) intrafemoral (IF; B) injection route. Each numbered sample 
represents a different primary leukemia from mice in Fig. 3 B injected into secondary recipients. Raw survival data, including numbers of animals in each 
cohort, are provided in Table S1. Data depicted are collated from four independent transplantation experiments.
Figure 5.  Transplantable clones with reduced IGF1R expression show compensatory PI3K–Akt activation. (A) Western blot and (B) flow cyto-
metric analysis of PTEN protein expression in primary and transplantable secondary E-IGF1Rneo leukemias. (C and D) Akt activation as measured by intra-
cellular phospho-Akt(Ser473) flow cytometry in response to stimulation with FBS (C) or (D) recombinant IGF-1 × (D) 10 min after 5-h serum starvation. 
(E) Steady-state level of Akt activation as measured by pAkt(Ser473) in transplantable E-IGF1R+/+ and E-IGF1Rneo (#3105) leukemias (n = 3 indepen-
dent mice for each cohort). For C and D, the five E-IGF1Rneo transplantable clones shown are (4 x #3115, 1 x #3112). Error bars indicate standard devia-
tion. *, P < 0.05; **, P < 0.01 (Student’s t test). Data depicted in A and B are representative of at least three independent experiments. Data depicted in C–E 
are representative of two independent experiments and include at least three independent mice per cohort per experiment.1814 Notch-IGF1R signaling supports LICs in T-ALL | Medyouf et al.
(GSI) to inhibit Notch signaling or vehicle control (DMSO). 
These  five  cell  lines  were  selected  because  they  undergo 
growth  arrest  upon  GSI  treatment  (Weng  et  al.,  2004;   
Palomero et al., 2007). To control for off-target effects of GSI, 
we also profiled cell lines that had been retrovirally trans-
duced with ICN1, and then treated with GSI or DMSO. 
ICN1, the intracellular domain of Notch1, is unaffected by 
GSI  treatment  and  thus  maintains  Notch  signaling  in  the 
presence of GSI (Weng et al., 2003, 2004). Further, because 
Notch1 induces transcription of c-Myc (Palomero et al., 2006b; 
Sharma et al., 2006; Weng et al., 2006), which in turn induces 
transcription of many other genes (Fernandez et al., 2003), we 
also profiled cells that had been transduced with c-Myc and then 
treated with GSI or DMSO to segregate Notch targets from   
c-Myc targets. We identified genes whose expression level most 
strongly correlated with Notch activity, but not with c-Myc, and 
noted the conspicuous presence of IGF1R on this list (Table S2) 
and in other published microarray datasets generated from GSI-
treated T-ALL cells (Fig. S6; Palomero et al., 2006b).
for hyperactivation of the Ras–Raf–MAPK pathway to ex-
plain the unique transplantability of these IGF1Rneo/neo clones 
(unpublished data). These few examples suggest PI3K–Akt 
activation may potentially be more important than Ras–Raf–
MAPK signaling in conferring LIC activity; however, further 
study is needed to clarify this issue.
IGF1R mRNA and protein expression  
is up-regulated by Notch
To  explore  mechanisms  that  may  support  the  high-level 
IGF1R expression required for LIC activity, we considered a 
potential role for Notch signaling. Notch has previously been 
shown  to  promote  activation  of  PI3K–Akt  in  developing   
thymocytes  (Ciofani  and  Zuñiga-Pflucker,  2005),  and  we 
noted in our expression profile datasets evidence for up-
regulation  of  IGF1R  by  Notch  signaling.  More  specifically,   
we performed microarray-based expression profiling of five 
human  T-ALL  cell  lines  (ALLSIL,  DND41,  HPBALL, 
KOPTK1, and TALL-1) treated with -secretase inhibitor 
Figure 6.  Inhibition of Notch signaling with GSI down-regulates IGF1R expression in human T-ALL cells. (A) qRT-PCR analysis of IGF1R mRNA 
in human T-ALL cell lines treated in vitro with -secretase inhibitor (GSI) to block Notch signaling versus DMSO vehicle (mock) for 2–10 d. Error bars indi-
cate standard deviation for assays performed in triplicate. (B and C) Flow cytometric analysis of surface IGF1R expression by human T-ALL cell lines 
treated with GSI versus DMSO vehicle for 6–8 d. Data are representative of multiple replicates. (D) Flow cytometric analysis of surface IGF1R expression 
by xenograft-expanded primary human T-ALL cells. Cells were cultured on MS5-DL1 feeders to stimulate Notch signaling versus MS5 control feeders and 
then treated with 1.0 µM compound E (GSI) for 2–4 d to block Notch signaling. Flow histograms for a representative case are depicted on the left, and 
results from six different patient samples are summarized on the right. Error bars indicate standard deviation. **, P < 0.01 (Student’s t test). At least 
20,000 gated live events were collected for all flow cytometry assays.JEM Vol. 208, No. 9 
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We also performed a similar expression profiling experi-
ment using the human T-ALL cell line, CUTLL1, which har-
bors a TcrB/Notch1 fusion gene that drives expression of a 
form  of  Notch1  resembling  E  (Palomero  et  al.,  2006a). 
CUTLL1 cells transduced with empty retrovirus (MigR1) or 
dominant-negative (DN) MAML1-GFP, a specific Notch   
inhibitor (Weng et al., 2003; Maillard et al., 2004; Weng et al., 
2004), were treated with GSI for 3 d, after which GSI was 
washed out to create a timed pulse of Notch signaling activity. 
Expression profiling was done on cells before washout and at 
2 and 4 h after washout to identify likely direct Notch1 target 
genes. We observed GSI washout up-regulated expression of 
IGF1R along with other known Notch1 target genes, such as 
Hes1, Hes4, Hes5, NRARP, and DTX1 in MigRI control 
cells, and that DN-MAML1-GFP partially or completely   
abrogated up-regulation of the same set of genes (Fig. S7).
To validate these expression profile data, we performed 
qRT-PCR for IGF1R mRNA. Notch-dependent T-ALL 
cell  lines  (ALLSIL,  DND41,  HPBALL,  KOPTK1,  and 
TALL-1) down-regulated IGF1R mRNA levels up to two-
fold when treated with GSI, whereas Notch-independent 
lines (Jurkat, PF382, and RPMI 8402) showed 6–14-fold 
down-regulation of IGF1R mRNA (Fig. 6 A). GSI blockade 
also down-regulated IGF1R protein levels 2–3 fold on aver-
age, as judged by flow cytometry and Western blotting of 
human  T-ALL  cell  lines  and  xenograft-expanded  primary 
samples (Fig. 6, B–D; and Fig. S8). This effect of GSI is likely 
specific to Notch, as DN-MAML1 also decreased IGF1R 
protein levels (Fig. 7 A), and the effect of GSI on IGF1R was 
rescued  by  retroviral  transduction  with  ICN1  (Fig.  7  B). 
Conversely, culture of xenograft-expanded primary human 
T-ALL cells on MS5 stromal cells expressing the Notch   
ligand DL1, but not MS5 control cells, increased IGF1R   
levels,  whereas  no  such  change  was  observed  for  the   
control marker CD45 (Fig. 7 C). In addition, this effect of 
DL1 ligand on IGF1R levels was abrogated by treatment 
with GSI (Fig. 6 D). Thus, these data are consistent with a 
role for Notch signaling in up-regulation of IGF1R ex-
pression in human T-ALL cells.
ICN1/CSL binds to an intronic IGF1R enhancer
Once cleaved from the plasma membrane by -secretase, 
ICN1 translocates to the nucleus where it forms a ternary 
complex on DNA with the DNA-binding factor CSL and 
the coactivator MAML1 to stimulate transcription of target 
genes (Aster et al., 2008). To define the regulatory elements 
through which Notch1 up-regulates target genes in an unbi-
ased fashion, we performed chromatin immunoprecipitation 
(ChIP)-Seq analysis on the human T-ALL cell line, CUTLL1, 
using antibodies directed against Notch1 and CSL (Wang   
et al., 2011). Alignment of sequencing reads from duplicate 
CSL  and  Notch1  libraries  identified  one  high-confidence 
ICN1/CSL-binding site within intron 20 of IGF1R at a   
position >250 kb 3 of the proximal promoter (Fig. 8 A). 
The next nearest ICN1/CSL-binding site lies 10.5 Mbp 5 
of the proximal promoter, making this 3 binding site the 
Figure 7.  Inhibition of Notch signaling with dominant-negative 
MAML1 and activation by ICN1 or DL1 ligand confirm IGF1R regulation 
by Notch. Flow cytometric analysis of surface IGF1R expression. (A) Human  
T-ALL cell lines were transduced with dominant negative Mastermind-like-1 
retrovirus (DN-MAML1-GFP) or empty virus control (MigRI). (B) Human T-ALL 
cell lines were transduced with ICN retrovirus (Mig ICN) and then treated with 
1.0 µM compound E (GSI) for 4 d (HPBALL and TALL-1) or 8 d (PF382) to block 
endogenous Notch signaling or DMSO vehicle (mock). Retrovirally transduced 
cells in A and B were discriminated from nontransduced cells by gating for GFP. 
Data depicted in A and B are representative of multiple replicates. (C) Xenograft-
expanded primary human T-ALL cells were cultured in vitro on MS5-DL1 feeders 
to stimulate Notch signaling versus control MS5 feeders. CD45 expression levels 
were also assessed simultaneously with IGF1R by flow cytometry. Flow histo-
grams for a representative case are depicted on the left, and results from six 
different patient samples are summarized on the right. Error bars indicate  
standard deviation. *, P < 0.05 (Student’s t test). At least 20,000 live events  
were collected within each gate for all flow cytometry assays.1816 Notch-IGF1R signaling supports LICs in T-ALL | Medyouf et al.
rapid  reloading,  indicating  that  ICN1/CSL  occupancy  is   
dynamic (Fig. 8 D).
The distant location of the putative ICN1/CSL response 
element in IGF1R suggested that it represents an enhancer. 
In support of this possibility, additional ChIP analyses docu-
mented recruitment of the histone acetyltransferases CREB-
binding protein (CBP) and p300, as well as RNA polymerase II, 
to this site (Fig. S9 A; Hatzis and Talianidis, 2002; Wang   
et al., 2005). Moreover, we observed enrichment of histone 
H3K4 mono- and dimethylation chromatin marks (charac-
teristic of enhancers) relative to H3K4 trimethylation marks 
(a feature of promoters; Heintzman et al., 2007), and low 
levels of the repressive trimethyl histone H3K27 chromatin 
mark (Fig. S9 B; Kirmizis et al., 2004). Finally, additional 
ChIP-Seq data showed a local decrease in H3K4 methyl-
ation at the precise site of the intronic IGF1R sequence-
paired site, indicating that this site lies in accessible chromatin 
that has been depleted of nucleosomes (Fig. S9 C). Collec-
tively,  these  data  support  the  presence  of  an  intronic 
only likely candidate response element for Notch1 regula-
tion. Motif analysis using recently developed algorithms   
derived from protein-binding microarrays (Del Bianco et al., 
2010) showed that the center of the region under the ICN1/
CSL-binding peak contains high (CATGGGAA) and mod-
erate (GCTGAGAA) affinity CSL sites oriented head-to-head   
and separated by a 17-bp spacer (Fig. 8 B). This architecture 
is typical of a sequence-paired site, a special type of Notch 
response element first identified in Drosophila enhancer of 
split (E[spl]) locus that is present in mammalian E(spl) homo-
logues such as Hes1 (Jarriault et al., 1995) and other genes 
such as preT (Liu et al., 2010). Loading of ICN1 onto this 
site  was  confirmed  by  ChIP/quantitative  PCR  (qPCR)   
analyses, performed on CUTLL1 cells and two additional   
human T-ALL cell lines, HPBALL and KOPTK1 (Fig. 8 C).   
In addition, GSI treatment of CUTLL1 cells depleted both 
CSL and ICN1 from this site (in line with work from Bray’s 
group indicating that ICN stabilizes CSL interactions with 
DNA; Krejcí and Bray, 2007), and GSI washout resulted in 
Figure 8.  ICN1/CSL binds dynamically to a site within intron 20 of human IGF1R. (A) Alignment of sequencing reads over intron 20 of the IGF1R 
locus from ChIP libraries prepared from the human T-ALL cell line, CUTLL1, with antibodies specific for Notch1 and CSL as compared with input cells.  
(B) Genomic DNA sequence from human IGF1R intron 20 (NT_010274.17: 14461410–14461610) with sequence-paired ICN1/CSL binding sites highlighted in 
bold and 17-bp spacer underlined. (C) ChIP/qPCR analysis of IGF1R intron 20 from three different human T-ALL cell lines using a Notch1-specific antibody 
as compared with preimmune antiserum. (D) ChIP/qPCR analysis of IGF1R intron 20 from CUTLL1 cells using antibodies specific for Notch1 and CSL com-
pared with control rabbit IgG. Cells were treated with GSI for 3 d to block Notch signaling (GSI x 3d) versus DMSO vehicle (DMSO). GSI was washed out, 
and cells were harvested 4 h later (GSI x 3d, then wash 4 h). Quantitation of immunoprecipitated DNA is expressed relative to input DNA (% input). Error 
bars indicate standard deviation for qPCR assays performed in triplicate. Numbers above bars in D indicate relative enrichment over control. ChIP libraries 
were prepared in duplicate, and local ChIP/qPCR analyses were performed twice. Representative results are shown.JEM Vol. 208, No. 9 
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retroviral transduction only partially rescued the pAkt re-
sponse to IGF1 in HPBALL cells (Fig. 9 C), whereas rescue 
was complete in PTENnull PF382 cells (Fig. 9 D; Palomero   
et al., 2007). Importantly, we confirmed retroviral IGF1R 
restored expression in GSI-treated cells to levels comparable 
to parental cells. Thus, although Notch inhibition can affect 
both IGF1R and PTEN expression, Notch contributes to 
supporting IGF1R expression at high levels, thereby allow-
ing T-ALL cells to respond more robustly to ambient levels 
of IGF-1/2.
DISCUSSION
We have presented data showing that IGF1R mediates im-
portant growth/survival signals in T-ALL cells, and that   
although moderate levels of signaling are adequate for main-
tenance of the bulk cell population, high levels are required 
for maintenance of LIC activity as indicated by serial trans-
plantation assay. The effect of reduced IGF1R signaling on 
disease transplantability could be caused by (a) a quantitative 
decrease in the number of leukemia stem cells; (b) a qualita-
tive  defect  in  self-renewal,  engraftment  ability,  and/or   
immune resistance of leukemia stem cells; or (c) a reduced 
Notch1-responsive  enhancer  in  human  IGF1R  that  is   
active in human T-ALL cells.
Physiological relevance of Notch-induced  
up-regulation of IGF1R
Notch signaling is likely one of several factors that influence 
IGF1R expression in T-ALL, as Notch inhibition results in 
only a two- to threefold decrease in surface IGF1R expres-
sion, on average. To assess whether this two- to threefold 
change in IGF1R protein levels has a significant effect on 
downstream  signaling,  we  measured  levels  of  intracellular 
phosphorylated Akt (pAkt) after pulsing serum-starved leu-
kemia  cells  with  recombinant  IGF-1.  We  observed  GSI-
treated cells to be 20-fold less responsive to IGF-1 than 
vehicle-treated control cells (Fig. 9 A). Although some of this 
effect is presumably caused by GSI effects on IGF1R expres-
sion, it has also been reported that Notch represses PTEN via 
HES-1 (Palomero et al., 2007), which could also impact the 
pAkt response. Indeed, GSI treatment induced PTEN ex-
pression in HPBALL cells; however, there was no detectable 
change in ALLSIL or DND41 cells (Fig. 9 B). Accordingly, 
restoration  of  IGF1R  expression  in  GSI-treated  cells  by   
Figure 9.  Notch-induced IGF1R expression enhances PI3K–Akt signaling in response to IGF1. (A) Flow cytometric analysis of intracellular phos-
pho-Akt levels. Cells were treated with GSI versus DMSO vehicle for 6–8 d, serum starved overnight, and then pulsed with recombinant IGF1 for 10 min 
before assay. (B) Western blot analysis of PTEN protein expression in cells treated with GSI versus mock for 4 d. (C and D) Flow cytometric analysis for 
intracellular phospho-Akt levels (left) and surface IGF1R levels (right). Cells were retrovirally transduced with Mig IGF1R, treated with GSI versus DMSO 
vehicle for 4 d, serum starved overnight, and then pulsed with recombinant IGF1 for 10 min before phospho-Akt assay. Transduced versus nontransduced 
cells within the same culture were distinguished by gating for GFP. Surface IGF1R expression level was also assessed by flow cytometry immediately  
before stimulation with IGF1. Filled grey histograms represent second antibody staining controls. At least 20,000 events were collected within each gate 
for all flow cytometry assays. Data depicted are representative of at least two independent experiments.1818 Notch-IGF1R signaling supports LICs in T-ALL | Medyouf et al.
inhibition of IGF1R signaling blocks growth/survival of bulk 
leukemia  cells  confirms  previous  results  with  PI3K–Akt/
mTOR inhibitors, and further illustrates that IGF1-dependent 
activation contributes in a substantive way to net PI3K–Akt 
signaling output. Perhaps most intriguing, however, is our 
observation that moderately decreased IGF1R signaling (as 
modeled by IGF1Rneo/neo leukemias) results in selective loss 
of LIC activity, yet leaves the growth and survival of bulk 
cells relatively unaffected. These findings suggest that LICs in 
T-ALL may be uniquely sensitive to inhibition of IGF1R 
signaling, and raise the possibility that pharmacologic IGF1R 
inhibitors now in clinical development could, in combina-
tion with standard regimens, enhance initial response to ther-
apy and reduce rates of disease relapse. Importantly, normal 
hematopoietic stem cell function appears not to be affected in 
IGF1Rneo/neo mice (unpublished data), suggesting a therapeu-
tic window exists in which IGF1R inhibitors block LIC   
activity yet have minimal effects on normal hematopoiesis.
MATERIALS AND METHODS
Mice. The IGF1Rneo line contains a PGK-neo-poly(A) expression cassette 
integrated within the second intron, resulting in decreased expression of   
full-length IGF1R (Holzenberger et al., 2000). The IGF1Rneo allele has been   
backcrossed  onto  the  C57BL/6  background  for  over  20  generations.   
Rosa26CreERT mice were obtained from The Jackson Laboratory. All trans-
plants  involving  mouse  cells  were  performed  using  C57BL/6J  (B6)  or 
B6(Cg)-Tyrc-2J/J  (“B6-albino”)  recipient  mice  (The  Jackson  Laboratory). 
Transplants  involving  human  cells  were  performed  using  NOD-Scid/
IL2Rc/ recipient mice. Animals were housed under specific pathogen–
free conditions at the BC Cancer Agency or Dana-Farber Cancer Institute 
animal facilities, and experimental studies performed under protocols ap-
proved by the University of British Columbia or Dana-Farber Institutional 
Review Boards, respectively. IGF1R genotyping was performed by multi-
plex assay with primers YNex (5-CCATGGGTGTTA AATGTTAAT-
GGC-3),  YNvl  (5-ATGAATGCTGGTGAGGGTTGTCTT-3)  and 
YNmt2  (5-ATCTTGGAGTGGTGGGTCTGTTTC-3),  as  previously 
described (Leneuve et al., 2001). Rosa26 genotyping was performed with 
primers RcreFW (5-AAAGTCGCTCTGAGTTGTTAT-3) and RcreRV 
(5-GCGAAGAGTTTGTCCTCAACC-3)  for  the  CreERT  allele,  and 
with  RwtFW  (5-GCACTTGCTCTCCCAAAGTC-3)  and  RwtRV   
(5-GGCGGATCACAAGCAATAAT-3) for the WT allele.
Plasmids. Retroviral vectors all used the MSCV-IRES-GFP (Mig) backbone. 
Mig ICN1, Mig E, and MSCV-DN-MAML1-GFP have been described pre-
viously (Aster et al., 1997; Weng et al., 2003). Mig IGF1R was generated by 
subcloning  a  4.2-kb  NotI-BamHI  fragment  containing  the  human  IGF1R 
cDNA from pBABE-bleo IGF1R (Addgene) into the Mig vector.
Retroviral  transduction/bone  marrow  transplantation.  High  titer, 
replication-defective  retroviral  supernatants  were  produced  by  transient 
transfection of PlatE cells as described previously (Medyouf et al., 2010). 
MSCV-based retroviral expression vectors included IRES-GFP cassettes 
for fluorescent tagging of transduced cells. Retroviral transduction of   
5-fluorouracil-treated or lineage-depleted (CD4, CD8, CD11b, B220, Ter119,   
and Gr1) bone marrow cells was performed as described previously (Medyouf   
et al., 2010). For primary transplants, WT C57BL/6 recipient mice were   
lethally irradiated (810 rads), and then injected intravenously with 30,000–
45,000 transduced GFP+ cells along with a minimum of 105 syngeneic whole 
bone marrow cells to ensure hematopoietic reconstitution. For serial transplants, 
0.5–1.0 × 106 GFP+ leukemia cells (from spleen or bone marrow of a moribund 
leukemic mouse) were injected into the tail vein (i.v.) or intramedullary 
probabilistic likelihood of engraftment/propagation of bulk 
leukemia cells. Notably, the last possibility does not presume 
the existence of leukemia stem cells in this model; however, 
we have generated data that supports that Notch T-ALLs   
indeed contain bona fide leukemia stem cells (unpublished 
data). Nonetheless, further studies will be required to distin-
guish between these possibilities.
We  have  also  shown  that  Notch  directly  up-regulates 
IGF1R expression in human T-ALL cells to an extent that 
substantially enhances their sensitivity to ambient ligand. It is 
worthwhile to note that we have found no evidence to sup-
port that Notch regulates IGF1R in mouse T-ALL cells. In 
fact, the sequence-paired ICN1/CSL-binding site within   
intron 20 of human IGF1R is not conserved in the mouse, 
suggesting that sequence divergence has decoupled this point 
of interaction between the Notch1 and IGF1R pathways. 
This is perhaps not surprising given that 40–90% of transcrip-
tion factor binding events are not conserved between mouse 
and human (Odom et al., 2007), underscoring the impor-
tance of studying human cells and animal models in parallel.
The existence of leukemia stem cells in human T-ALL is 
supported  by  xenograft  transplantation  assays  (Cox  et  al., 
2007; Chiu et al., 2010; Gerby et al., 2011) and also in mouse 
models of T-ALL by transplantation into SCID or Rag1/ 
immunocompromised recipients (Guo et al., 2008; Tremblay 
et al., 2010). The precise cellular compartment most enriched 
for LIC activity appears to vary from patient to patient and 
between different animal models, and likely depends on the 
particular complement of genetic alterations present in the 
leukemic clone and the particular transplant recipient used 
(Cox et al., 2007; Quintana et al., 2008; Chiu et al., 2010; 
Gerby et al., 2011). Nonetheless, it is interesting to note that 
Notch signaling has been shown to contribute to human   
T-ALL LIC activity in nonobese diabetic (NOD)/Scid trans-
plantation assays (Armstrong et al., 2009). As Notch signaling 
is mediated through transcriptional activation, identification 
of downstream target genes has received much attention. In 
several such studies, c-Myc has been identified as a direct 
transcriptional  target  of  Notch1  (Palomero  et  al.,  2006b; 
Sharma et al., 2006; Weng et al., 2006), and may constitute 
part of a self-renewal genetic program similar to that demon-
strated in induced pluripotent stem cells (Takahashi and   
Yamanaka, 2006; Takahashi et al., 2007). Notch may also 
repress PTEN (Palomero et al., 2007), and thus potentiate 
PI3K–Akt/mTOR signaling which may also promote LIC 
activity (Yilmaz et al., 2006).
Most prior studies have focused on signaling via IL-7   
(Dibirdik et al., 1991; Barata et al., 2004a,b,c, 2005; González-
Garcia et al., 2009; Shochat et al., 2011; Silva et al., 2011) or 
mutational activation of intermediates in the PI3K–Akt path-
way (Palomero et al., 2007; Gutierrez et al., 2009). The im-
portance of PI3K–Akt activation in T-ALL is underscored by 
multiple studies showing that PI3K–Akt/mTOR inhibitors 
block growth/survival of T-ALL cells (Avellino et al., 2005; 
Wei et al., 2006; Palomero et al., 2007; Chiarini et al., 2009; 
Cullion et al., 2009). Notably, our observation that complete JEM Vol. 208, No. 9 
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(Altromin) and mice were allowed to feed ad libitum. For induction of Cre-
ERT activity in vitro, 4-OHT (Sigma-Aldrich) was dissolved in ethanol and 
added to culture media at 50 nM final concentration.
Expression profiling. Total RNA was isolated by TRIzol (Invitrogen) ex-
traction or RNeasy Mini kit (QIAGEN) and submitted to the McGill Uni-
versity/Génome Québec Innovation Centre or Harvard Medical School 
Biopolymers Core for expression profiling using Affymetrix HG-U133 Plus 
2.0 GeneChips. Data were analyzed using dChip software (Schadt et al., 
2001). Microarray data are available from the Gene Expression Omnibus   
accession no. GSE29959.
Quantitative real-time PCR. Total RNA was extracted after cell lysis in 
TRIzol reagent (Invitrogen). First-strand cDNA was generated by reverse 
transcription with SuperScript III (Invitrogen) using a mix of random 15-mer 
and anchored oligo(dT)20+1 primers, and then amplified using Platinum 
SYBR Green qPCR SuperMix-UDG (Invitrogen) and the following specific 
primer sets: hIGF1R forward 5-ACTTACTCGGACGTCTGGTCCTTC-3,   
hIGF1R reverse 5-ATCTTGGGGTTATACTGCCAGCAC-3 for IGF1R, 
and hActB RT5 5-CGCGAGAAGATGACCCAGAT-3plus hActB RT3 
5-GAT AGC ACA GCC TGG ATA GCA AC-3 for -actin. Each sample 
was assayed in triplicate using a Dyad Disciple thermal cycler equipped with 
Chromo4 optical head (Bio-Rad Laboratories). Expression levels were cal-
culated by the Ct method with normalization to -actin.
ChIP. ChIP was performed with the ChIP Assay kit (Millipore). In brief, 
cells were cross-linked with 1% formaldehyde for 10 min at 37°C, lysed in 
1% SDS, and 10 mM EDTA, 50 mM Tris, pH 8.1, and then sonicated to 
obtain DNA fragments from 200–600 bp. Chromatin was then immuno-
precipitated with the following antibodies: Notch1(Tc; Aster et al., 1997), 
CSL (gift from E. Kieff, Brigham and Women’s Hospital, Boston, MA), 
H3K4me1  (ab8895;  Abcam),  H3K4me2  (07–030;  Millipore),  H3K4me3 
(07–745; Millipore), CBP (ab10489; Abcam), p300 (sc-585; Santa Cruz 
Biotechnology,  Inc.),  RNA  pol2  (05623B;  Millipore),  and  mouse  IgG 
(12–371; Millipore) as control. After overnight incubation with antisera   
at 4°C, immunoprecipitated chromatin was captured with Protein A-agarose 
beads, washed, and eluted. After reversal of cross-links, DNA was pu-
rified using the QIAquick PCR purification kit (QIAGEN). Input con-
trol DNA was also prepared in parallel, omitting the immunoprecipitation 
steps. Primers used for qPCR after ChIP were as follows: IGF1Rchip for-
ward  5-GGTGGGTGAGGGAGAGCGGT-3  and  IGF1Rchip  reverse 
5-GGCTGCGTCCCAGGCAGTTT-3.
ChIP-Seq and data analysis. ChIP-Seq libraries were prepared according 
to the Illumina ChIP DNA library preparation kit. After addition of adap-
tors, libraries were amplified by 18 cycles of PCR, size selected (150–250 bp) 
by electrophoresis, and purified using a QIAGEN gel extraction kit. After 
quality control testing on an Agilent 2100 Bioanalyzer, the library was sub-
jected to deep sequencing using an Illumina Genome Analyzer II in the 
Harvard Medical School Biopolymers Core facility. Sequencing reads were 
aligned to human genome build hg18 and analyzed using CisGenome   
(Ji et al., 2008). One-sample and two-sample analyses were performed using 
100-bp windows and reads of >10 bp.
Online supplemental material. Fig. S1 shows Akt response to stimula-
tion with IGF1 and insulin and effects of BMS-536924 inhibitor in T-ALL 
cells. Fig. S2 shows effects of the BMS-536924 inhibitor on T-ALL cell 
growth and viability in vitro. Fig. S3 shows resistance to growth inhibi-
tion by IGF1R blocking antibody correlates with reduced surface IGF1R 
expression. Fig. S4 shows effects of IGF1R deletion on T-ALL develop-
ment in vivo and cell growth/viability in vitro. Fig. S5 demonstrates in vivo 
efficacy of the IGF1R inhibitor BMS-754807 in a mouse T-ALL model. 
Fig. S6 shows that IGF1R is a Notch target gene in an independent ex-
pression profiling dataset. Fig. S7 shows IGF1R is a Notch target gene in 
the human T-ALL cell line, CUTLL1. Fig. S8 shows Western blot analysis 
space of the femur (intrafemoral [IF]) of nonirradiated C57BL/6 recipients. 
We define LIC activity here as the ability to produce aggressive disease in 
syngeneic/congenic secondary recipients under these transplant conditions 
within 20 wk.
Human  leukemia  samples.  Cryopreserved  lymphoblast  samples  were 
provided by collaborating institutions. Primary samples were obtained at ini-
tial diagnosis with informed consent from patients or their legal guardians   
or as discarded pathological material under approved Institutional Review 
Board protocols at the Karmanos Cancer Institute, Hôpital Armand-Trousseau, 
Hopital Saint-Louis, BC Cancer Agency, and BC Children’s and Women’s 
Hospital following guidelines established by the Declaration of Helsinki. Ex-
pansion of primary human T-ALL cells in irradiated NOD-Scid/IL2Rc/ 
mice has been described previously (Medyouf et al., 2010).
In vitro culture of primary T-ALL cells. Primary human T-ALL cells 
were cultured on MS5-DL1/MS5 stromal feeder cells as previously de-
scribed (Medyouf et al., 2010). Primary mouse T-ALL cells were cultured 
without feeders in complete media with supplemental cytokines.
Cell lines. IGF1R knockout mouse embryo fibroblasts (R-cells) that were 
engineered to re-express human IGF1R (R+) were a gift from P. Sorensen 
(BC Cancer Agency, Vancouver, British Columbia, Canada). All established 
T-ALL cell lines were grown in RPMI 1640 medium supplemented with 
10% FCS, 1 mM sodium pyruvate, 2 mM L-glutamine, and antibiotics.
Ligand stimulation assay. Leukemia cells were serum starved overnight, 
and then stimulated for 10 min with either recombinant IGF-1 (PeproTech), 
recombinant insulin (Sigma-Aldrich), or fetal calf serum (Invitrogen), at in-
dicated doses. Cells were then fixed immediately by addition of formalde-
hyde  (Electron  Microscopy  Services)  to  1.5%,  and  permeabilized  with 
ice-cold methanol for at least 1 h before analysis by flow cytometry.
In vitro proliferation/apoptosis assays. Cells were pulsed with 10 µM 
BrdU for 1 h at 37°C, and then fixed/stained with anti-BrdU antibody   
according to manufacturer instructions (FITC or APC BrdU Flow kit; BD) 
and analyzed by flow cytometry with gating for mouse and human leukemia 
cells by GFP- and hCD45-positive events, respectively. Cell growth was also 
measured  by  CellTiter-Blue  assay  (Promega)  or  Ki67-Alexa  Fluor  647/
Hoechst staining (BD Biosciences). Apoptotic cells were identified by stain-
ing  with  Annexin  V-FITC/7-aminoactinomycin  or  active  caspase-3-PE 
(BD). Cell viability was assessed by propidium iodide exclusion and analysis 
by flow cytometry.
Antibody  reagents.  Antibodies  directed  against  the  following  proteins 
were used: IGF1R (sc-712, Santa Cruz Biotechnology), PTEN (Y184, 
Abcam), and ERK2 (sc-154, Santa Cruz Biotechnology) for Western blots, 
and hCD45 (eBioscience), CD4 (L3T4; eBioscience), CD8a (53–6.7, Bio-
Legend), IGF1Ra (IR3; EMD), and P-AKT (S473; Cell Signaling Tech-
nology) for flow cytometry.
Flow cytometry. Acquisition was performed on FACSCalibur or LSRII 
cytometers (BD) and data analyzed using FlowJo software (Tree Star, Inc.).
Drugs. IGF1R inhibitors BMS-536924 and BMS-754807 were obtained 
under Material Transfer Agreement from the manufacturer. BMS-536924 
was resuspended in DMSO at 10 mM, then serially diluted in Hank’s Bal-
anced Salt Solution (Invitrogen) before addition to culture media. BMS-
754807 was resuspended in PEG400:H2O (80:20 by volume) at 5 mg/ml 
final concentration before administration to mice. An azide-free preparation 
of IR3 antibody was used for IGF1R blocking studies (EMD). -Secretase 
inhibitor XXI (compound E) was used at 1.0 µM final concentration for all 
studies (EMD). GSI washout was performed by washing cells twice with 
prewarmed, complete culture medium. For induction of CreERT activity in 
vivo, 1 g tamoxifen (Sigma-Aldrich) was admixed per 1 kg mouse chow 1820 Notch-IGF1R signaling supports LICs in T-ALL | Medyouf et al.
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